Transcatheter Aortic Valve Replacement: Current Bioprostheses and Future

Transcatheter aortic valve replacement (TAVR) is a treatment for aortic stenosis in patients who are inoperable or have high risk for surgery [1,2]. Since the first in-man TAVR was performed in France in 2002, this procedure has been practiced for 10 years, and over 50,000 patients received valve implantation in more than 40 countries [2,3]. The PARTNER Trial showed the survival rate of patients after TAVR and Surgery was similar at 1 year, and TAVR resulted in a significantly lower mortality rate than standard medical therapy [4,5].